Cipla Misses Second-Quarter Profit Estimates as US Sales Are Muted
Cipla’s consolidated net profit fell to ₹878 crore ($92.2 million) in the quarter, as muted Revlimid sales and stiff competition weighed on its US business.
Cipla, the country's third-largest drugmaker by revenue, missed second-quarter profit estimates on Tuesday, as muted sales of generic Revlimid and stiff competition weighed on its US business.The company's consolidated net profit fell to ₹878 crore ($92.2 million) in the quarter ende…